Last reviewed · How we verify
Autologous Adipose Cells Therapy — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Autologous Adipose Cells Therapy (Autologous Adipose Cells Therapy) — CERM INC..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Autologous Adipose Cells Therapy TARGET | Autologous Adipose Cells Therapy | CERM INC. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Autologous Adipose Cells Therapy CI watch — RSS
- Autologous Adipose Cells Therapy CI watch — Atom
- Autologous Adipose Cells Therapy CI watch — JSON
- Autologous Adipose Cells Therapy alone — RSS
Cite this brief
Drug Landscape (2026). Autologous Adipose Cells Therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/autologous-adipose-cells-therapy. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab